CClinicalTrials.gg
CompletedNCT04584229ChemsexUpdated Nov 18, 2020

Chemsex, Perceived Risks and Coping Strategies.

An observational study in Sexual; Sexual Desire, Illicit Drugs and MSM, sponsored by University Hospital, Montpellier. Completed at 1 site in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-18.

Sponsored by University Hospital, Montpellier · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
15
Ages
18 Years and older
Sex
Male
01

Study summary

The research hypothesis is that access to prevention and harm and risk reduction associated with the use of psychoactive substances in a sexual context is insufficient for MSM practicing chemsex. This would lead to a lack of awareness of the risks taken and insufficient or inadequate strategies to protect themselves.

This qualitative study has a comprehensive objective. The aim is to identify the risks perceived by MSM practicing Chemsex and their coping strategies. The study is based on individual semi-directed interviews and focus group. The criteria for inclusion are: an age greater than or equal to 18 years, being a man having sex with men and having used psychoactive substances in a sexual context at least once in the past 12 months. Participants were recruited through a gay geo-social networking app on mobile phones on a voluntary basis. At the same tim+e, flyers presenting the study are also distributed to the "chemsex" consultations at the Montpellier University Hospital in France as well as to an association fighting against AIDS in Montpellier.

Data are subjected to an inductive method analysis, bringing out by constant comparison conceptualizing categories illustrating the experience and making it possible to identify and understand the risks felt and the coping strategies.

02

Conditions studied

  • Sexual; Sexual Desire
  • Illicit Drugs
  • MSM

Keywords

  • screening
  • MSM
  • Qualitative research
  • HIV transmission
  • men who have sex with men
  • Risk Reduction Behavior
  • Harm Reduction
  • recreational drugs
  • Sexualised drug use
03

In context

Lead sponsor

University Hospital, Montpellier is the lead sponsor of 1,244 studies on the registry; 225 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

men who have sex with other men

Inclusion criteria

  • an age greater than or equal to 18 years
  • being a man having sex with men
  • having used psychoactive substances in a sexual context at least once in the past 12 months.

Exclusion criteria

Exclusion criteria:

  • to refuse to participate to the study
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
15 participants (actual)
Patient registry
No

Groups and cohorts

  • question not suitable for study

    question not suitable for study

    Other: Intervention

Interventions

  • OtherIntervention

    Intervention: comprehensive individual or collective interview, recorded and transcribed

06

What researchers measure

Primary outcomes

  1. Chemsex Paretic Risk Assessment

    Chemsex Paretic Risk Assessment

    Time frame: 1 day

Secondary outcomes

  1. Description of the population leaving Chemsex

    Description of the population leaving Chemsex

    Time frame: 1 day

07

Study locations

1 site
  • Uhmontpellier
    Montpellier, 34295, France
08

References and documents

Individual participant data

Plan to share: Undecided — NC

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04584229
Lead sponsor
University Hospital, Montpellier
Responsible party
Sponsor
First posted
Oct 12, 2020
Start date
Oct 30, 2019
Primary completion
Dec 30, 2019
Completion
Dec 30, 2019
Last update
Nov 18, 2020

Study contacts

Hélène Donnadieu-Rigole, MD, PHD
study director · University Hospital, Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion